SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 9.99% Stake in MAINZ BIOMED N.V.
Beneficial Ownership Disclosure
Investment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a significant passive ownership stake of 9.99% in MAINZ BIOMED N.V. as of December 31, 2024.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' have filed a Schedule 13G indicating beneficial ownership in MAINZ BIOMED N.V.
- As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 230,967 Ordinary Shares of MAINZ BIOMED N.V.
- This ownership represents 9.99% of the total outstanding Ordinary Shares of the issuer.
- Armistice Capital, LLC, a Delaware entity, is an investment adviser, and Steven Boyd, a U.S. citizen, is its managing member.
- The shares are held by Armistice Capital Master Fund Ltd., an investment advisory client of Armistice Capital, LLC, which exercises shared voting and dispositive power over these securities.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of MAINZ BIOMED N.V.
Sentiment
Score: 6
Explanation: The disclosure of a significant stake by a reputable investment firm is generally viewed as a positive signal, indicating investor confidence, although the filing itself is purely factual and passive in nature.
Positives
- The disclosure of a significant stake by an institutional investor like Armistice Capital may signal confidence in MAINZ BIOMED N.V.'s prospects.
- The passive nature of the investment, as indicated by the Schedule 13G filing, suggests that the investor is not seeking to disrupt current management or operations.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance.
Industry Context
This filing is a standard regulatory disclosure of a significant passive investment in a publicly traded company. It does not provide specific insights into broader industry trends or competitive landscape, but rather reflects an investment decision by a specific fund within the biotechnology or healthcare sector, where MAINZ BIOMED N.V. operates.
Stakeholder Impact
- Shareholders: The disclosure provides transparency regarding a significant ownership stake, which can influence market perception and potentially share price. It indicates a large institutional investor has taken a position, which some shareholders may view positively.
- Company Management: Awareness of a significant passive investor on the shareholder register.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which required the filing of this statement, indicating the beneficial ownership position as of this date. |
| 02/14/2025 | Date the Schedule 13G statement was signed and filed with the SEC. |
Keywords
MAINZ BIOMED N.V., Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Investment, Ordinary Shares, SEC Filing, Stake, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.